References
1. ICH, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
(1999).
2. H.G. Brittain, Ed., Polymorphism in Pharmaceutical Solids (2nd edition, Informa Healthcare, London).
3. J. Haleblian and W. McCrone, J. Pharm. Sci., 58 (58), 911–929 (1969).
4. T.L. Threlfall, Analyst, 120 (10) 2435–2460 (1995).
5. D. Singhal D and W. Curatolo, Adv. Drug Delivery Rev.
56 (5) 335–347 (2004).
6. S.L. Price, Acc. Chem. Res.
42 (1) 117–126 (2009).
7. M.A. Neumann and M.A. Perrin, J. Phys. Chem. B, 109 (32), 15531–15541 (2005).
8. M.A. Neumann, J. Phys. Chem. B, 112 (32), 9810–9829 (2008).
9. M.A. Neumann, F.J.J. Leusen, and J. Kendrick, Angew. Chem. Int. Ed. 47 (13), 2427–2430 (2008).
10. G.M. Day et al., Acta Cryst. B
65 (2) 107–125 (2009).
11. S.R.Chemburkar et al., Org. Process Res. Dev.
4 (5), 413–417 (2000).
12. Y. Kobayashi et al., "Int. J. Pharm
193 (2), 137–146 (2000).
13. J. Aaltonen et al., Eur. J. Pharm. Biopharm. 71 (1), 23–37 (2009).
For additional insight on screening strategies in solid-state chemistry, see http://pharmtech.findpharma.com/pharmtech/Ingredients/Polymorph-Screening-Strategies-A-QampA-with-Jan-Ol/ArticleStandard/Article/detail/647428.
|
